SM 88

Drug Profile

SM 88

Alternative Names: SM88

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tyme Technologies
  • Developer The Joseph Ahmed Foundation; Tyme Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Free radical stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer; Prostate cancer
  • Phase I Cancer
  • Clinical Phase Unknown Ewing's sarcoma
  • Preclinical Breast cancer; Glioma; Osteosarcoma

Most Recent Events

  • 12 Jun 2018 Updated efficacy data from a phase I trial and Compassionate Use Programme in Cancer released by Tyme
  • 09 Apr 2018 Tyme Technologies has patent protection for SM 88
  • 06 Apr 2018 Tyme Technologies enters into a collaboration with the The Joseph Ahmed Foundation to conduct investigator -sponsored trials of SM 88 for Sarcoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top